TokenPost·
Krystal Biotech Q3 Estimates Point to 29.4% Revenue Growth
Earnings per share are estimated at $1.92, down 27.8% year over year. Results are due before U.S. markets open Monday, Nov. 2.
More news
- TokenPostCoreWeave Shares Fall 10% Friday Amid Financing Concerns and Tech Weakness
- TokenPostU.S. Bitcoin ETFs Take In $440.8 Million Over Four Sessions
- TokenPostU.S. XRP ETFs Add $8.43 Million as Franklin Templeton ETF Leads Inflows
- crypto.newsUber earns 1.5 extra days of yield in Canton blockchain pilot
- TokenPostBaron Capital Plans to Oppose Oasis Nominees at Vail Resorts Meeting
- CoinDeskExperts divided over Binance hack asset freezes, warn recovery is another matter